# Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)

> **NCT01123941** · PHASE1 · COMPLETED · sponsor: **Novartis** · enrollment: 50 (actual)

## Conditions studied

- Typhoid Fever

## Interventions

- **BIOLOGICAL:** Typherix
- **BIOLOGICAL:** NVGH Vi-CRM197

## Key facts

- **NCT ID:** NCT01123941
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2010-06
- **Final completion:** 2010-11
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2014-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01123941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01123941, "Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01123941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*